| Authors: |
Villaruz LC; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Jin J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Wang H; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Lee JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Luke JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Rhee JC; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Waqar SN; Washington University School of Medicine, St. Louis, Missouri, USA., Shapiro GI; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cleary J; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Davar D; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Burns TF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Verma R; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Amin M; University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA., Appleman L; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Ciombor KK; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Davis EJ; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Dees EC; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Kim EJ; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Cardin D; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Christner SM; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Deppas J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Parise AM; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Schmitz JC; Program in Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Guerrouahen BS; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Suchko M; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Contreras A; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Li L; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA., Ferry-Galow KV; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Jiwani S; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Bakkenist CJ; Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Chu E; Montefiore Einstein Cancer Canter, Bronx, New York, USA., Gore SD; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Beumer JH; The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, USA. |
